

**DEPARTMENT OF LABOR****Employment and Training  
Administration**

[TA-W-57,729]

**Teleflex Medical Pilling Weck,  
Incorporated Including Leased  
Workers of Adecco Research Triangle  
Park, NC; Amended Certification  
Regarding Eligibility To Apply for  
Worker Adjustment Assistance and  
Alternative Trade Adjustment  
Assistance**

In accordance with section 223 of the Trade Act of 1974 (19 U.S.C. 2273), and section 246 of the Trade Act of 1974, (26 U.S.C. 2813), as amended, the Department of Labor issued a Certification of Eligibility to Apply for Worker Adjustment Assistance and Alternative Trade Adjustment Assistance on August 30, 2005, applicable to workers of Teleflex Medical, including leased workers of Adecco, Research Triangle Park, North Carolina. The notice was published in the **Federal Register** on October 6, 2005 (70 FR 58478).

At the request of the company, the Department reviewed the certification for workers of the subject firm. The workers are engaged in the production of medical devices.

New information shows that that all workers separated from employment at the subject firm had their wages reported under a separate unemployment insurance (UI) tax account for Pilling Weck, Incorporated.

Accordingly, the Department is amending the certification to properly reflect this matter.

The intent of the Department's certification is to include all workers of Teleflex Medical, Research Triangle Park, North Carolina who was adversely affected increased imports.

The amended notice applicable to TA-W-57,729 is hereby issued as follows:

All workers of Teleflex Medical, Pilling Weck, Incorporated, including leased workers of Adecco, Research Triangle Park, North Carolina, who became totally or partially separated from employment on or after August 12, 2004, through August 30, 2007, are eligible to apply for adjustment assistance under Section 223 of the Trade Act of 1974, and are also eligible to apply for alternative trade adjustment assistance under section 246 of the Trade Act of 1974.

Signed at Washington, DC, this 8th day of December 2005.

**Richard Church,**

*Certifying Officer, Division of Trade  
Adjustment Assistance.*

[FR Doc. E5-7602 Filed 12-20-05; 8:45 am]

**BILLING CODE 4510-30-P**

**NATIONAL AERONAUTICS AND  
SPACE ADMINISTRATION**

[Notice (05-170)]

**Notice of Prospective Patent License**

**AGENCY:** National Aeronautics and Space Administration.

**ACTION:** Notice of Prospective Patent License.

**SUMMARY:** This notice is issued in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i). NASA hereby gives notice of its intent to grant a partially exclusive license in the United States to practice the inventions described and claimed in Foreign Patent No. 0423277, JSC Docket No. MSC-21293-1-EP, "Bio-Reactor Cell Culture Process", Foreign Patent No. 1987294, JSC Docket No. MSC-21293-1-JP, "Bio-Reactor Cell Culture Process", International Application No. PCT/US98/06826, JSC Docket No. MSC-22859-1-EP, European Application No. 98915320.0 entitled "Production of Functional Proteins: Balance of Shear Stress and Gravity", International Application No. PCT/US98/06826, JSC Docket No. MSC-22859-1-JP, Japanese Application No. 10-540983 entitled "Production of Functional Proteins: Balance of Shear Stress and Gravity", International Application No. PCT/US98/06826, JSC Docket No. MSC-22859-1-CA, Canadian Application No. 2286349 entitled "Production of Functional Proteins: Balance of Shear Stress and Gravity", International Application No. PCT/US98/06826, JSC Docket No. MSC-22859-1-IL, Israeli Application No. 132264 entitled "Production of Functional Proteins: Balance of Shear Stress and Gravity", International Application No. PCT/US98/06826, JSC Docket No. MSC-22859-1-MX, Mexican Application No. 999265 entitled "Production of Functional Proteins: Balance of Shear Stress and Gravity", and International Application No. PCT/US98/06826, JSC Docket No. MSC-22859-1-BR, Brazilian Application No. 98915320.0 entitled "Production of Functional Proteins: Balance of Shear Stress and Gravity" to Renautus Bio Therapeutics, LLC, having its principal place of business in Baton Rouge, LA. The patent rights in the

inventions have been assigned to the United States of America as represented by the Administrator of the National Aeronautics and Space Administration. The prospective partially exclusive license will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.

**DATES:** The prospective exclusive license may be granted unless, within fifteen (15) days from the date of this published notice, NASA receives written objections including evidence and argument that establish that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Competing applications completed and received by NASA within fifteen (15) days of the date of this published notice will be treated as objections to the grant of the contemplated partially exclusive license. Objections submitted in response to this notice will not be made available to the public for inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

**ADDRESSES:** Objections relating to the prospective license may be submitted to Patent Counsel, Office of Chief Counsel, Johnson Space Center, Mail Code AL, 2101 NASA Parkway, Houston, Texas 77058.

**FOR FURTHER INFORMATION CONTACT:** Kurt G. Hammerle, Patent Attorney, NASA Johnson Space Center, Mail Stop AL, Houston, TX 77058-8452, Telephone: (281) 483-1001, Facsimile: (281) 483-6936. Information about other NASA inventions available for licensing can be found online at <http://technology.nasa.gov/>.

Dated: December 15, 2005.

**Keith T. Sefton,**

*Deputy General Counsel, Administration and Management.*

[FR Doc. E5-7635 Filed 12-20-05; 8:45 am]

**BILLING CODE 7510-13-P**

**SECURITIES AND EXCHANGE  
COMMISSION****Proposed Collections; Comment  
Request**

*Upon Written Request, Copies Available From:* Securities and Exchange Commission, Office of Filings and Information Services, Washington, DC 20549.

**Extensions:**

Form SE; OMB Control No. 3235-0327;

SEC File No. 270-289.

Form ID; OMB Control No. 3235-0328;

SEC File No. 270-291.